Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) General Counsel Sells $125,750.00 in Stock

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the sale, the general counsel now directly owns 167,618 shares of the company’s stock, valued at $843,118.54. This trade represents a 12.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Maravai LifeSciences Stock Performance

MRVI stock opened at $4.93 on Monday. The stock’s 50 day simple moving average is $5.42 and its 200 day simple moving average is $7.13. Maravai LifeSciences Holdings, Inc. has a 12-month low of $4.28 and a 12-month high of $11.56. The firm has a market cap of $1.24 billion, a P/E ratio of -3.01 and a beta of -0.07. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.09) earnings per share (EPS) for the quarter. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The business had revenue of $65.20 million during the quarter, compared to the consensus estimate of $67.58 million. During the same quarter in the previous year, the business posted ($0.02) earnings per share. As a group, equities research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on MRVI shares. Wolfe Research began coverage on shares of Maravai LifeSciences in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Royal Bank of Canada lowered their target price on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Guggenheim began coverage on Maravai LifeSciences in a report on Thursday, December 19th. They issued a “neutral” rating for the company. William Blair restated a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. Finally, The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and reduced their target price for the company from $7.00 to $4.25 in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences has an average rating of “Hold” and an average price target of $10.28.

Hedge Funds Weigh In On Maravai LifeSciences

Several institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its holdings in shares of Maravai LifeSciences by 1,172.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock worth $33,658,000 after purchasing an additional 3,731,924 shares during the last quarter. Jennison Associates LLC lifted its stake in Maravai LifeSciences by 0.3% in the fourth quarter. Jennison Associates LLC now owns 2,990,414 shares of the company’s stock valued at $16,298,000 after buying an additional 9,769 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Maravai LifeSciences by 6.3% during the third quarter. Geode Capital Management LLC now owns 2,752,077 shares of the company’s stock valued at $22,874,000 after acquiring an additional 162,601 shares during the period. Point72 DIFC Ltd bought a new position in shares of Maravai LifeSciences during the third quarter worth about $22,108,000. Finally, Systematic Financial Management LP grew its position in shares of Maravai LifeSciences by 14.7% during the third quarter. Systematic Financial Management LP now owns 1,612,161 shares of the company’s stock worth $13,397,000 after acquiring an additional 206,499 shares during the last quarter. 50.25% of the stock is owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.